Industry sponsorship bias in cost effectiveness analysis: registry based analysis

22 June 2022 - The Tufts Cost-Effectiveness Analysis Registry was used to identify all CEAs published in Medline between 1976 and ...

Read more →

Amylyx Pharmaceuticals announces Health Canada approval of Albrioza for the treatment of ALS

13 June 2022 - Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ...

Read more →

BeiGene announces PDUFA goal date extension for U.S. sNDA for Brukinsa for the treatment of CLL/SLL

13 June 2022 - Following additional data submission to FDA demonstrating ORR superiority over ibrutinib as determined by IRC, PDUFA goal ...

Read more →

Mallinckrodt announces resubmission of terlipressin to the FDA for the treatment of hepatorenal syndrome

13 June 2022 - Mallinckrodt today announced the resubmission of the Company's new drug application to the U.S. FDA for ...

Read more →

FDA approves first systemic treatment for alopecia areata

13 June 2022 - Today, the U.S. FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, ...

Read more →

Pembrolizumab for adjuvant treatment of renal cell carcinoma

10 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using pembrolizumab ...

Read more →

Zai Lab announces breakthrough therapy designations granted for repotrectinib in China

10 June 2022 - Breakthrough therapy designations granted for ROS1 positive non-small-cell lung cancer patients pretreated with one prior line of ...

Read more →

Harvard professors continue to push misconceptions to justify drug price controls

10 June 2022 - The biopharmaceutical industry performed wonderfully during the COVID-19 pandemic.  ...

Read more →

NRx Pharmaceuticals provides update on breakthrough therapy designation request for Zyesami (aviptadil)

10 June 2022 - NRx Pharmaceuticals today announced that the U.S. FDA denied the breakthrough therapy designation request for Zyesami (aviptadil) ...

Read more →

FDA approves new oncology drugs quicker than EMA

10 June 2022 - The US FDA is quicker to approve new oncology drugs compared with the EMA, according to ...

Read more →

Everest Medicines announces approval of Trodelvy in China for second-line metastatic triple negative breast cancer

10 June 2022 - Everest plans to launch commercial sales of Trodelvy in China in Q4, 2022. ...

Read more →

Hundreds of thousands set to benefit as NICE final draft guidance recommends new treatment to prevent heart attacks and strokes in people with raised blood fats

10 June 2022 - NICE has today published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular ...

Read more →

U.S. Senators ask regulators to clear drug patent 'thickets'

9 June 2022 - Letter asks U.S. Patent and Trademark Office to crack down on "highly similar" patents for single ...

Read more →

Roxadustat for treating anaemia in people with chronic kidney disease

9 June 2022 - After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Document  on the ...

Read more →

Drug importation is dangerous and won’t lower prices

9 June 2022 - Federal and state governments continually insert themselves into the medical marketplace in an attempt to lower prescription ...

Read more →

PHARMAC joins ACT’s call for a medicines strategy

8 June 2022 - “It appears that everyone wants a dedicated Medicines Strategy apart from Andrew Little, who is too ...

Read more →